[Skip to Content]
[Skip to Content Landing]
May 4, 2005

Drug-Eluting Stents in Acute Myocardial InfarctionIs Science Catching Up With Practice?

Author Affiliations

Author Affiliations: Division of Cardiology, University of North Carolina at Chapel Hill (Drs Cohen and Ohman)

JAMA. 2005;293(17):2154-2156. doi:10.1001/jama.293.17.2154

In the last 3 to 4 years, the use of drug-eluting stents in clinical practice has revolutionized interventional cardiology. Two pivotal trials using sirolimus- and paclitaxel-eluting stents and reporting previously unheard-of single-digit restenosis rates1,2 heralded a new era for interventional cardiology, suggesting that the most vexing problem for intervention, namely, restenosis, had finally been tackled. These 2 trials predominantly studied patients undergoing elective procedures and found target-lesion revascularization rates of approximately 3% to 4% and postprocedure myocardial infarction rates that ranged from 2.8% to 3.5%.

First Page Preview View Large
First page PDF preview
First page PDF preview